The Daily Toke

March 26, 2026

# Cannabis Policy Hits a Crossroads as Markets Mature and States Move Independently

The U.S. cannabis landscape is fracturing into a patchwork of competing regulatory visions as states forge ahead with their own policies while the federal government remains gridlocked. The Army's decision to allow recruits with single marijuana possession convictions to enlist without a waiver—effective April 20—signals a significant cultural shift on cannabis in the military, yet this same week saw Ohio lawmakers overhaul their voter-approved recreational law with restrictions that criminalize public consumption and ban THC beverages from non-dispensary retailers. The contrast is stark: one institution opening doors while others are slamming them shut.

💰 MONEY MOVES The legal cannabis market is showing signs of maturity after experiencing its first revenue decline in recorded history last year. Whitney Economics projects U.S. legal marijuana sales will reach $30.5 billion in 2026, up 4.9% from 2025's $29.1 billion, with growth accelerating to $43.3 billion by 2030. But the driver of this rebound isn't euphoric expansion—it's market normalization. Supply saturation has crushed prices, and consumer behavior has fundamentally shifted from the post-COVID spending patterns that once inflated the market. New York and Ohio's expanded retail access barely offset nationwide pricing compression, meaning the era of triple-digit growth is over. The industry is transitioning from a speculative boom into something resembling a mature consumer market.

Meanwhile, states are racing in opposite directions on legalization. Tennessee Democrats have introduced the "Pot for Potholes Act," which would legalize recreational marijuana for adults 21+ and dedicate 15% state tax revenue to highway infrastructure repair—a pragmatic pitch to skeptics who might otherwise resist normalization. Louisiana is taking a more cautious approach, with a limited pilot program that restricts recreational sales to existing medical operators, effectively preserving a two-company duopoly. Idaho's medical cannabis ballot measure is nearing qualification. In Massachusetts, lawmakers are eyeing a ballot question that would essentially reverse the 2016 legalization vote, though legislators quickly identified a fatal flaw: allowing adults to possess up to an ounce and gift it freely while prohibiting sales would simply resurrect the black market they hoped to replace.

Federal legislation remains stalled despite 16 cannabis bills filed in the current congressional session. The Marijuana Opportunity Reinvestment and Expungement (MORE) Act leads with 62 sponsors and would fully deschedule cannabis, while the STATES 2.0 Act would allow interstate commerce and protect businesses from federal enforcement. But Rep. James Comer (R-KY) is pushing Congress to delay new federal hemp restrictions set for November 2026—a delay that affects a $28.4 billion market for hemp-derived THC products. The Centers for Medicare & Medicaid Services has announced details of a pilot program allowing Medicare coverage for up to 3 milligrams of THC in hemp-derived CBD products starting April 1, though that coverage remains vulnerable if President Trump's recently signed law to recriminalize hemp THC takes effect without modification. 🚀 THIS IS COOL Utah Gov. Spencer Cox signed legislation to fund clinical trials into psychedelic-assisted therapy for military veterans with serious mental health conditions, and Georgia lawmakers advanced a bill to expand medical cannabis access by allowing vaping and adding new qualifying conditions. These state moves toward therapeutic access contrast sharply with the federal classification that keeps cannabis on Schedule I—a status that has persisted for over 50 years despite Nixon's own Shafer Commission recommending decriminalization in 1971.

🤔 THINK ABOUT IT If the federal government is genuinely concerned about protecting public health and youth safety, why does it keep one zero-overdose plant on Schedule I while alcohol—the number-one drug-related killer of teenagers—sits completely unscheduled and freely available at gas stations nationwide? The policy architecture suggests the concern isn't actually about harm reduction; it's about something else entirely. Meanwhile, the Army is quietly signaling that a single marijuana conviction shouldn't disqualify someone from military service, state legislatures are drafting infrastructure-funding schemes around cannabis tax revenue, and Medicare is about to start covering hemp-derived THC products. Normalization isn't coming from Washington. It's arriving from everywhere else—one state, one institution, one market at a time.

March 26, 2026

# Hemp Ban Watch: March 2026

Multiple states are moving swiftly to restrict or eliminate intoxicating hemp products, reshaping a market that emerged from the legal gray area created by the 2018 Farm Bill. Texas will eliminate smokeable hemp products effective March 31, joining Ohio, which implemented its ban on Friday. The moves signal an accelerating national pattern of state-level crackdowns on THC-containing hemp that manufacturers have legally produced for years under federal law.

Texas's new regulations will eliminate pre-rolled joints, hemp flower, and other smokeable products—items that currently comprise more than 50 percent of some retailers' inventory. 💰 MONEY MOVES The state is simultaneously raising licensing fees for manufacturers from $287 to $10,000 per facility and retail registrations from $144 to $4,000, a cost structure industry leaders say will force many businesses to close. Lukas Gilkey, chief executive of Hometown Hero, a major hemp manufacturer, told reporters: "They did a ban with their own regulatory scheme. The way they wrote the rules, it's going to eliminate a lot of products that are fully legal and fully fine and not harmed anyone." Texas will allow edibles and beverages to continue sales, a distinction that leaves the market partially intact but dramatically reduced.

Ohio's restrictions took effect March 20 after a judge rejected an 11th-hour legal challenge. The law bans intoxicating hemp products, THC and CBD beverages, and smokable forms—a sweeping restriction that affects an estimated 6,000 Ohio businesses. Mark Fashian, president of Midwest Analytical Solutions in Delaware, Ohio, told retailers he works with to pull all inventory from shelves immediately or face felony charges: "If I were you, I would get every product off the shelf and out of the store." Cleveland-based Saucy Seltzer, California cannabis drink maker Uncle Arnie's, and Illinois hemp manufacturer Organic Pharma Techs filed a federal lawsuit arguing that without immediate relief, they would "go out of business in Ohio on March 19, 2026 and thus suffer irreparable harm."

South Carolina's Senate has advanced its own sweeping regulations restricting hemp ingestibles, requiring 21-year-old age verification, moving 10-milligram THC drinks into liquor stores, and creating new DUI thresholds. The debate stretched for days as lawmakers argued over everything from euphoria levels and potency comparisons to whether cold beverages should be allowed, fearing they could be consumed more casually. 🤔 THINK ABOUT IT Alcohol is the number-one drug-related killer of teenagers in the United States, yet these same legislators are proposing unprecedented restrictions on a product with zero recorded overdose deaths in human history while legal alcohol remains freely available at every convenience store.

The federal government is also moving toward restriction. Congress voted in November to ban products containing 0.4 milligrams of total THC per container, though that restriction includes a one-year implementation delay. The new federal threshold is stricter than the 0.3 percent dry-weight THC standard set by the 2018 Farm Bill, which created the legal market these states are now dismantling. Joey Ellwood, a hemp farmer in Tuscarawas County, Ohio, noted that customers using hemp products for stress, sleep, pain, and anxiety now face difficult choices: "They might have to turn to pharmaceuticals. They might have to drive across state lines."

March 26, 2026

Researchers have delivered a stark verdict on medical cannabis and mental health: the largest review to date found no strong evidence that cannabinoid-based treatments work for anxiety, depression, or PTSD, despite millions of Americans using cannabis specifically for these conditions. Published in The Lancet Psychiatry, the University of Sydney analysis examined the safety and efficacy of medicinal cannabis across a range of mental health disorders and concluded that routine use could actually do more harm than good. Lead author Dr. Jack Wilson warned that cannabis use for these conditions may increase risks of psychotic symptoms, cannabis use disorder, and delay people from seeking proven treatments—a significant finding given that roughly 50 percent of the estimated 27 percent of U.S. and Canadian adults aged 16-65 who use cannabis medically report doing so to manage mental health symptoms.

The study did identify some limited evidence of benefit for cannabis use disorder itself, autism, insomnia, and Tourette's syndrome, though researchers emphasized the quality of evidence remains low and cannot justify widespread use without robust medical support. The findings arrive as federal policy is moving in a different direction entirely. 💰 MONEY MOVES The Centers for Medicare & Medicaid Services announced details of a pilot program launching April 1 that will cover up to $500 annually in hemp-derived CBD and THC products for Medicare beneficiaries—allowing up to 3 milligrams of THC per product. This coverage decision has sparked controversy, with critics arguing that CMS may be circumventing FDA drug approval standards by treating cannabis products as medicine without the traditional scientific framework required for other pharmaceuticals.

The federal coverage move also collides directly with a provision signed into law by President Trump to recriminalize hemp-derived THC products, with a CBD product ban set to take effect by November. 🤔 THINK ABOUT IT Policymakers are simultaneously expanding Medicare coverage for hemp cannabinoids while moving to ban them—a contradiction that underscores the policy chaos surrounding cannabis regulation. Daniel Kruger, a cannabis policy researcher at the University at Buffalo, argues that outright bans are unnecessary if proper regulation is in place. "A better approach would be to regulate these products, mandate their testing, and have a certificate of analysis accessed through a QR code," Kruger said. "Regulate similar substances similarly." Industry analysts estimate that CBD wellness and recreational product sales could reach between $8.5 billion and $13 billion in 2026, making the regulatory uncertainty consequential for millions of consumers and businesses.

While mental health applications face evidentiary headwinds, cannabis compounds are showing genuine promise in other areas. 🚀 THIS IS COOL Researchers at Hebrew University of Jerusalem found that CBD and CBG—non-psychoactive cannabinoids—improved liver function in mouse models of non-alcoholic fatty liver disease (NAFLD), a condition affecting roughly 24 percent of U.S. adults. The compounds appeared to enhance hepatic energy and lysosomal function, with CBD and CBG acting like a "backup battery" for liver health under metabolic stress. Separately, cannabis compounds showed promise in calming brain inflammation associated with Alzheimer's disease, suggesting that targeting inflammation may be as important as targeting protein buildup. These findings remain preliminary—animal studies don't always translate to human benefit—but they point toward specific therapeutic pathways worth pursuing.

Congress continues to signal normalization momentum with 16 cannabis bills filed in the 2025-2026 session, more than any previous session. The Marijuana Opportunity Reinvestment and Expungement (MORE) Act leads with 62 sponsors and would fully remove marijuana from the Controlled Substances Act, end federal prohibition, and establish automatic expungement for certain federal marijuana offenses. Other bipartisan proposals include the Hemp Planting Predictability Act, which would delay new federal hemp restrictions set for November, and the CLIMB Act, which would allow state-legal marijuana businesses to list on major stock exchanges like Nasdaq. These legislative efforts contrast sharply with the mental health data: policymakers are moving toward normalization and commerce while scientific evidence increasingly suggests cannabis is not a reliable treatment for the conditions that drive much of current medical use. The gap between policy direction and clinical evidence suggests future regulatory frameworks will need to become more precise about which cannabis applications have genuine science behind them—and which don't.

March 26, 2026

Texas hemp retailers are facing a regulatory crackdown that could eliminate roughly half the industry's most popular products when new rules take effect March 31. The Texas Department of State Health Services' revised regulations will require testing for total THC content—including THCA, a non-intoxicating compound that converts to delta-9 THC when heated—effectively banning smokeable products like flower and prerolled joints. 💰 MONEY MOVES The licensing fee increases are staggering: manufacturer licenses will jump from $258 to $10,000 annually, while retail registrations will spike from $155 to $5,000—a more than 3,000% increase. According to the Texas Cannabis Policy Center, this regulatory approach will hand approximately 50% of the legal market to illicit operators, making the state less safe. Business owners like Jacob Warner of Alamo Bud Co. report that smokeable products represent 70% of their sales, meaning March 31 could force them to clear shelves and explore closing locations entirely.

The new rules extend beyond product composition bans. They mandate stricter age verification for customers under 21, require detailed recordkeeping, tighten packaging guidelines, and implement multiple rounds of product testing during manufacturing and before retail sale. Edibles and beverages will remain legal because they contain lower THC concentrations or fall under different regulatory oversight—the Texas Alcoholic Beverage Commission hasn't banned them—creating an uneven marketplace where some cannabis products survive while others vanish overnight. 🤔 THINK ABOUT IT The state is implementing these rules with a four-week implementation window, giving retailers minimal time to adapt inventory, rebuild business models, and avoid financial collapse. Experts like Heather Fazio questioned this compressed timeline: "Imagine being a business and finding out that not only are your registration fees going up significantly, but also 50%—maybe even 70%—of the products that you sell now have to be taken off the shelves in a matter of weeks."

This crackdown arrives after Governor Greg Abbott vetoed a total hemp ban during last year's legislative session, stating the industry needed regulation rather than extinction. That veto potentially saved thousands of businesses occupying millions of square feet across Texas's $8 billion hemp retail sector. Yet Abbott's September executive order directing DSHS to revise hemp regulations has essentially produced a regulatory ban instead of a legislative one—what industry leaders call "a ban with their own regulatory scheme." At least one East Texas vape shop has already filed a lawsuit challenging the new rules.

The Texas situation mirrors emerging patterns nationwide. Ohio's hemp restrictions took effect March 20, banning THC beverages and gummies while limiting synthetic cannabinoids. South Carolina passed legislation regulating hemp-derived THC products, though restricting where low-dose gummies and drinks can be sold. These state-level moves create a fragmented landscape where federally legal hemp products become illegal depending on which state line you cross. Veterans who use legal THC products for PTSD, chronic pain, and anxiety face shrinking options as states tighten restrictions—potentially pushing users toward unregulated black markets or less-safe alternatives.

The DSHS defended its March 31 implementation date by stating "immediate enforcement is necessary," claiming the rules serve consumer safety and comprehensive industry oversight. Supporters argue stricter regulations address loopholes that allowed unregulated cannabis products to proliferate in smoke shops, gas stations, and CBD stores. Yet the rapid rollout, combined with massive fee increases and product bans affecting half the market, suggests an approach more aligned with restriction than regulation. The next four weeks will determine whether Texas's hemp industry adapts, relocates, or dissolves into the illicit market the state claims it wants to prevent.